- Positive IND-enabling data for Radio-DARPin MP0712 targeting DLL3 in small cell lung cancer
- Initial preclinical data on mesothelin-focused Radio-DARPin for solid tumors
- Proof-of-concept data for Switch-DARPin T cell engager demonstrating tumor regression
Molecular Partners (MOLN, Financial) has revealed significant advancements in its oncology pipeline at the American Association for Cancer Research (AACR) 2025. The company highlighted three key developments from its preclinical studies, focusing on its proprietary DARPin platform technology.
The most advanced program, MP0712, targets DLL3 in small cell lung cancer and has completed its IND-enabling studies. The data from these studies indicate high tumor uptake and favorable safety profiles in mouse models. The IND filing is set for 2025, with initial clinical data anticipated in the latter half of the year.
Additionally, Molecular Partners introduced promising preclinical data for a new Radio-DARPin targeting mesothelin (MSLN) in solid tumors. This development addresses the historical challenge of interference from shed MSLN in therapeutic applications. The preclinical models showed strong tumor accumulation while selectively binding to membrane-bound MSLN without affecting soluble MSLN.
The third development involves the Switch-DARPin T cell engager, a logic-gated system that activates T cells specifically in the presence of tumor markers such as MSLN and EpCAM. Preclinical studies demonstrated significant tumor regression in mice without peripheral T cell activation, suggesting a favorable safety profile.
These advancements, all in partnership with Orano Med for the Radio-DARPin programs, illustrate Molecular Partners' strategic focus on leveraging DARPin therapeutics to address unmet medical needs in oncology. The MP0712 program, in particular, is poised to enter clinical trials in 2025, marking a critical milestone for the company.
